In this supplement we added new drug monographs with stability and compatibility data for these drugs: BLINATUMOMAB, BRIVARACETAM, ERIBULIN MESYLATE, FERRIC CARBOXYMALTOSE, DECITABINE, FOMEPIZOLE, GLOBULIN, IMMUNE (HUMAN) AND HYALURONIDASE, IBANDRONATE SODIUM, IDARUCIZUMAB, ISAVUCONAZONIUM SULFATE, RASBURICASE, SODIUM FERRIC GLUCONATE COMPLEX, SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM NITRITE, TEMOZOLOMIDE, VINCRISTINE SULFATE LIPOSOME, and ZOLEDRONIC ACID.
Also, we added new stability information for these existing drug monographs: AZTREONAM, BACLOFEN, BUSULFAN, CARBOPLATIN, CEFPIROME SULFATE, CEFEPIME HYDROCHLORIDE, CEFTAZIDIME, DORIPENEM, FENTANYL CITRATE, HEPARIN SODIUM, HETASTARCH, KETAMINE HYDROCHLORIDE, LEVETIRACETAM, MEROPENEM, NITROPRUSSIDE SODIUM, PACLITAXEL, PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM, TACROLIMUS, TRANEXAMIC ACID, and VANCOMYCIN HYDROCHLORIDE.
In addition new compatibility information is reported for over 20 existing drug monographs, including entries for CEFTOLOZANE AND TAZOBACTAM, IRINOTECAN HYDROCHLORIDE, TEDIZOLID PHOSPHATE, and SUGAMMADEX.